1
|
Samartgis JR, Schachte L, Hazi A, Crowe SF. Piracetam, an AMPAkine drug, facilitates memory consolidation in the day-old chick. Pharmacol Biochem Behav 2012; 103:353-8. [PMID: 22940587 DOI: 10.1016/j.pbb.2012.08.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2011] [Revised: 08/13/2012] [Accepted: 08/19/2012] [Indexed: 10/28/2022]
Abstract
Piracetam is an AMPAkine drug that may have a range of different mechanisms at the cellular level, and which has been shown to facilitate memory, amongst its other effects. This series of experiments demonstrated that a 10mg/kg dose of piracetam facilitated memory consolidation in the day-old chick when injected from immediately until 120min after weak training (i.e. using a 20% v/v concentration of methyl anthranilate) with the passive avoidance learning task. Administration of piracetam immediately after training led to memory facilitation which lasted for up to 24h following training. This dose of the AMPAkine was not shown to facilitate memory reconsolidation. These findings support the contention that application of the AMPAkine piracetam facilitates memory using a weak training task, and extend the range of actions previously noted with NMDA-related agents to those which also facilitate the AMPA receptor.
Collapse
Affiliation(s)
- Jodi R Samartgis
- School of Psychological Science, Faculty of Science, Technology and Engineering, La Trobe University, Bundoora, Victoria 3086, Australia
| | | | | | | |
Collapse
|
2
|
Grossman L, Stewart A, Gaikwad S, Utterback E, Wu N, DiLeo J, Frank K, Hart P, Howard H, Kalueff AV. Effects of piracetam on behavior and memory in adult zebrafish. Brain Res Bull 2011; 85:58-63. [DOI: 10.1016/j.brainresbull.2011.02.008] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2010] [Revised: 02/15/2011] [Accepted: 02/22/2011] [Indexed: 11/26/2022]
|
3
|
Yan R, Nguyen Q, Gonzaga J, Johnson M, Ritzmann RF, Taylor EM. Reversal of cycloheximide-induced memory disruption by AIT-082 (Neotrofin) is modulated by, but not dependent on, adrenal hormones. Psychopharmacology (Berl) 2003; 166:400-7. [PMID: 12605287 DOI: 10.1007/s00213-002-1350-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2002] [Accepted: 11/08/2002] [Indexed: 10/20/2022]
Abstract
RATIONALE AIT-082 (Neotrofin), a hypoxanthine derivative, has been shown to improve memory in both animals and humans. In animals, adrenal hormones modulate the efficacy of many memory-enhancing compounds, including piracetam and tacrine (Cognex). OBJECTIVE To investigate the role of adrenal hormones in the memory-enhancing action of AIT-082. METHODS Plasma levels of adrenal hormones (corticosterone and aldosterone) in mice were significantly reduced by surgical or chemical (aminoglutethimide) adrenalectomy or significantly elevated by oral administration of corticosterone. The effects of these hormone level manipulations on the memory-enhancing activity of AIT-082 and piracetam were evaluated using a cycloheximide-induced amnesia/passive avoidance model. RESULTS As previously reported by others, the memory enhancing action of piracetam was abolished by adrenalectomy. In contrast, the memory enhancement by 60 mg/kg AIT-082 (IP) was unaffected. However, a sub-threshold dose of AIT-082 (0.1 mg/kg, IP) that did not improve memory in control animals did improve memory in adrenalectomized animals. These data suggested that, similar to piracetam and tacrine, the memory enhancing action of AIT-082 might be inhibited by high levels of adrenal hormones. As expected, corticosterone (30 and 100 mg/kg) inhibited the action of piracetam, however no dose up to 100 mg/kg corticosterone inhibited the activity of AIT-082. CONCLUSIONS These data suggest that while AIT-082 function is not dependent on adrenal hormones, it is modulated by them. That memory enhancement by AIT-082 was not inhibited by high plasma corticosterone levels may have positive implications for its clinical utility, given that many Alzheimer's disease patients have elevated plasma cortisol levels.
Collapse
Affiliation(s)
- Rongzi Yan
- NeoTherapeutics Inc, 157 Technology Drive, Irvine, CA 92618, USA
| | | | | | | | | | | |
Collapse
|
4
|
Zarrindast MR, Hadi M, Homayoun H, Postami P, Shafaghi B, Khavandgar S. The role of alpha-adrenoceptors in the amnestic effect of intracerebroventricular dexamethasone. Pharmacol Res 2002; 46:339-44. [PMID: 12361696 DOI: 10.1016/s1043661802001482] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Corticosteroids exert dual enhancing or impairing effects on cognitive functions. While their memory-enhancing effects have been well investigated, the mechanisms involved in their amnestic effects are not completely understood. Thus, we examined the role of alpha-adrenoceptors on dexamethasone-induced amnesia using step-through passive avoidance test in rat. Intracerebroventricular (i.c.v.) injection of dexamethasone (5 and 10 microg per rat) decreased the retention latencies. Likewise, intraperitoneal administration of alpha(2)-adrenoceptor agonist clonidine (0.1-0.3 mg kg(-1)) but not alpha(2)-adrenoceptor antagonist yohimbine (0.5-2 mg kg(-1)) decreased the retention latency. Yohimbine pre-treatment decreased the amnestic effects of dexamethasone or dexamethasone plus clonidine. On the other hand, intraperitoneal administration of alpha(1)-adrenoceptor agonist phenylephrine (0.5-2 mg kg(-1)) per se increased, while prazosin at 2 mg kg(-1) decreased the retention latency. Administration of phenylephrine before dexamethasone completely reversed the amnestic effect of the latter, while prozosin did not affect dexamethasone-induced amnesia. These data suggest that dexamethasone may induce its amnestic effect through activation of alpha(2)-adrenoceptors, leading to decreased alpha(1)-adrenergic activity.
Collapse
Affiliation(s)
- Mohammad Reza Zarrindast
- Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran.
| | | | | | | | | | | |
Collapse
|
5
|
Loscertales M, Rose SP, Daisley JN, Sandi C. Piracetam facilitates long-term memory for a passive avoidance task in chicks through a mechanism that requires a brain corticosteroid action. Eur J Neurosci 1998; 10:2238-43. [PMID: 9749752 DOI: 10.1046/j.1460-9568.1998.00234.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We investigated the effects of piracetam, a nootropic, on learning and memory formation for a passive avoidance task in day-old chicks. To test for the possible cognitive-enhancing properties of piracetam, a weak learning version of this task--whereby chicks maintain a memory to avoid pecking at a bead coated in a diluted aversant for up to 10 h--was used. Post-training (5, 30 or 60 min), but not pretraining, injections of piracetam (10 or 50 mg/kg, i.p.) increased recall for the task when the chicks were tested 24 h later. Because previous studies showed that long-term memory for the passive avoidance task is dependent upon a brain corticosteroid action, and because the efficacy of piracetam-like compounds is also modulated by corticosteroids, we tested whether the facilitating effect of piracetam was dependent upon a corticosteroid action through specific brain receptors (mineralocorticoid receptor and glucocorticoid receptor). First, increased plasma levels of corticosterone were found 5 min after piracetam injection. In addition, intracerebral administration of antagonists for each receptor type (RU28318, for mineralocorticoid receptors, and RU38486 for glucocorticoid receptors; i.c.) given before the nootropic inhibited the facilitative effect of piracetam on memory consolidation. These results give further support to a modulatory action of piracetam on the mechanisms involved in long-term memory formation through a neural action that, in this learning model, requires the activation of the two types of intracellular corticosteroid receptors.
Collapse
Affiliation(s)
- M Loscertales
- Brain and Behaviour Research Group, The Open University, Milton Keynes, UK
| | | | | | | |
Collapse
|
6
|
Abstract
To evaluate the efficacy of piracetam therapy, 76 children with breath-holding spells admitted to the Outpatient Clinic of Dicle University Medical Faculty Paediatrics Department and Bakirköy State Hospital, Paediatrics Department between 1988 and 1990 and 1991 and 1996, respectively, were included in this placebo-controlled trial. Diagnosis of breath-holding spells was made for all cases by medical history, pediatric physical examination, electroencephalogram, and laboratory findings. Placebo or piracetam as suspension was administered to patients on a randomized basis; piracetam was administered to children in suspension 40 mg/kg/day in 2 divided doses for a period of 2 months. Of the 76 children enrolled, 39 received piracetam and 37 received placebo. Overall, control of breath-holding spells was observed in 92.3% of the patients in the group taking piracetam as compared with 29.7% in the group taking placebo (P < .05). No differences between the 2 groups in adverse events or side effects were observed. Complete blood count, biochemical profile, and urine analysis taken before and after treatment revealed no change from beginning to end and no difference between the 2 groups. It is suggested that piracetam is a safe and effective drug, with an incidence of side effects no different from that of placebo, for the treatment of breath-holding spells.
Collapse
Affiliation(s)
- M M Donma
- Ministry of Health, Bakirköy State Hospital, Clinics of Paediatrics, Istanbul, Turkey
| |
Collapse
|
7
|
Giovannini MG, Casamenti F, Bartolini L, Pepeu G. The brain cholinergic system as a target of cognition enhancers. Behav Brain Res 1997; 83:1-5. [PMID: 9062653 DOI: 10.1016/s0166-4328(97)86038-x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- M G Giovannini
- Department of Preclinical and Clinical Pharmacology, University of Florence, Italy
| | | | | | | |
Collapse
|
8
|
Saito R, Ishiharada N, Ban Y, Honda K, Takano Y, Kamiya H. Vasopressin V1 receptor in rat hippocampus is regulated by adrenocortical functions. Brain Res 1994; 646:170-4. [PMID: 8055336 DOI: 10.1016/0006-8993(94)90073-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Two subtypes of arginine vasopressin (AVP) receptors (V1 and V2) have been distinguished. In this study, we examined the characteristics of AVP binding in rat hippocampus and the effects of bilateral adrenalectomy and adrenal steroids on its [3H]AVP binding. [3H]AVP binding to rat liver and the hippocampal membranes was strongly inhibited by the V1 antagonist, OPC-21268. ADX resulted in a significant decrease in the Bmax of AVP binding in the hippocampus. Chronic treatment with aldosterone and corticosterone restored the ADX-induced reduction, but treatment with dexamethasone did not. These results suggest that the AVP V1 receptor in the hippocampus is regulated by adrenocortical neuroregulatory functions.
Collapse
Affiliation(s)
- R Saito
- Department of Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, Japan
| | | | | | | | | | | |
Collapse
|
9
|
Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. BRAIN RESEARCH. BRAIN RESEARCH REVIEWS 1994; 19:180-222. [PMID: 8061686 DOI: 10.1016/0165-0173(94)90011-6] [Citation(s) in RCA: 247] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Nearly three decades have now passed since the discovery of the piracetam-like nootropics, compounds which exhibit cognition-enhancing properties, but for which no commonly accepted mechanism of action has been established. This review covers clinical, pharmacokinetic, biochemical and behavioural results presented in the literature from 1965 through 1992 (407 references) of piracetam, oxiracetam, pramiracetam, etiracetam, nefiracetam, aniracetam and rolziracetam and their structural analogues. The piracetam-like nootropics are capable of achieving reversal of amnesia induced by, e.g., scopolamine, electroconvulsive shock and hypoxia. Protection against barbiturate intoxication is observed and some benefit in clinical studies with patients suffering from mild to moderate degrees of dementia has been demonstrated. No affinity for the alpha 1-, alpha 2-, beta-, muscarinic, 5-hydroxytryptamine-, dopamine, adenosine-A1-, mu-opiate, gamma-aminobutyric acid (GABA) (except for nefiracetam (GABAA)), benzodiazepine and glutamate receptors has been found. The racetams possess a very low toxicity and lack serious side effects. Increased turnover of different neurotransmitters has been observed as well as other biochemical findings, e.g., inhibition of enzymes such as prolylendopeptidase. So far, no generally accepted mechanism of action has, however, emerged. We believe that the effect of the racetams is due to a potentiation of already present neurotransmission and that much evidence points in the direction of a modulated ion flux by, e.g., potentiated calcium influx through non-L-type voltage-dependent calcium channels, potentiated sodium influx through alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor gated channels or voltage-dependent channels or decreases in potassium efflux. Effects on carrier mediated ion transport are also possible.
Collapse
Affiliation(s)
- A H Gouliaev
- Department of Chemistry, Aarhus University, Denmark
| | | |
Collapse
|
10
|
Mondadori C. In search of the mechanism of action of the nootropics: new insights and potential clinical implications. Life Sci 1994; 55:2171-8. [PMID: 7997076 DOI: 10.1016/0024-3205(94)00398-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The positive action of nootropics on the memory has up to now primarily been discussed in the context of effects on energy metabolism and cholinergic or glutaminergic neurotransmission. Recent findings have shown that the memory-enhancing effect is steroid-sensitive. Since corticosteroids are potent modulators of gene transcription, it appears possible that the nootropics may exert a modulatory action on protein synthesis. This assumption is supported on the one hand by the fact that the nootropics improve the memory even if they are administered several hours after the learning trial, and on the other hand by the observation that their memory-enhancing effect does not become detectable until 16-24 hours after the treatment and learning trial. Provided the memory-enhancing effect in animal experiments and the therapeutic effect in patients come about by way of the same mode of action, the fact that high levels of corticosteroids suppress the effects of the nootropics could also have clinical implications: in the light of the observation that the majority of Alzheimer patients have elevated steroid levels it could explain why there is always only a small proportion of patients in clinical trials that respond to treatment with nootropics.
Collapse
Affiliation(s)
- C Mondadori
- CIBA-GEIGY LTD, Pharmaceutical Research Division, Basel, Switzerland
| |
Collapse
|
11
|
Abstract
Up to now, the memory-enhancing effect of the nootropics has chiefly been investigated in the context of effects on energy metabolism and on cholinergic and glutamatergic neurotransmission. Recent studies have also shown that the effect on memory is steroid-sensitive. The present review article summarizes the available results and discusses them in the context of a new hypothesis on the mechanism of action and with respect to clinical implications.
Collapse
Affiliation(s)
- C Mondadori
- CIBA-GEIGY Limited, Pharmaceutical Research Division, Basel, Switzerland
| |
Collapse
|
12
|
Mondadori C, Weiskrantz L. NMDA receptor blockers facilitate and impair learning via different mechanisms. BEHAVIORAL AND NEURAL BIOLOGY 1993; 60:205-10. [PMID: 8297316 DOI: 10.1016/0163-1047(93)90371-n] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The NMDA receptor blockers CGP 37849 (competitive) and MK 801 (noncompetitive) improve retention performance in the step-down passive avoidance situation but impair it in the step-through dark avoidance. It is suggested that the drugs in the two tasks act on different underlying processes. Whereas the memory facilitating effects of both drugs can be suppressed by pretreatment with either aldosterone or corticosterone, their negative effects on retention were steroid-insensitive. This set of results suggests that the mechanisms by which NMDA blockers improve memory are different from the mechanisms by which they block memory.
Collapse
Affiliation(s)
- C Mondadori
- Pharmaceutical Research Division, Ciba-Geigy Ltd., Basel, Switzerland
| | | |
Collapse
|
13
|
Pitsikas N, Algeri S. Effect of oxiracetam on scopolamine-induced amnesia in the rat in a spatial learning task. Pharmacol Biochem Behav 1992; 43:949-51. [PMID: 1448491 DOI: 10.1016/0091-3057(92)90430-n] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The effects of the nootropic agent 4-hydroxy-2-oxopyrrolidinoacetamide (oxiracetam) on memory and performance impairments induced by scopolamine were evaluated in the Morris water maze task. No effect was seen on the performance of rats when treated with oxiracetam (30 mg/kg, IP) alone. Task performance of scopolamine (0.2 mg/kg, SC)-treated rats was impaired as compared to that of control animals. The behavioral deficits expressed in the task by scopolamine treatment were attenuated by the same dose of oxiracetam.
Collapse
Affiliation(s)
- N Pitsikas
- Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | | |
Collapse
|
14
|
Mondadori C, Buerki H, Borkowski J, Radeke E, Ducret T, Glatt A. CGS 5649 B, a new compound, reverses age-related cognitive dysfunctions in rats. BEHAVIORAL AND NEURAL BIOLOGY 1992; 57:149-56. [PMID: 1586354 DOI: 10.1016/0163-1047(92)90653-l] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
CGS 5649 B improves the learning performance of aged rats in a one-way active-avoidance situation. If, under reversed conditions, treated aged rats are also tested for passive avoidance, they show "place learning," which our findings have demonstrated to be typical of young rats. The effects of the substance are not confined to these experimental models nor are they species specific: it also facilitates passive avoidance in mice and social learning in rats. The compound is effective if administered before or immediately after the learning trial.
Collapse
Affiliation(s)
- C Mondadori
- Pharmaceutical Research Department, Ciba-Geigy Limited, Basel, Switzerland
| | | | | | | | | | | |
Collapse
|
15
|
Häusler A, Persoz C, Buser R, Mondadori C, Bhatnagar A. Adrenalectomy, corticosteroid replacement and their importance for drug-induced memory-enhancement in mice. J Steroid Biochem Mol Biol 1992; 41:785-9. [PMID: 1314083 DOI: 10.1016/0960-0760(92)90425-i] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Adrenalectomy blocks the memory-improving effect of piracetam-like compounds in mice. If this blockade is due to the removal of endogenous corticosteroids, replacement therapy with exogenous corticosteroids should reinstate the effects on memory. The present experiments were designed to determine the appropriate replacement dose (concentration in the drinking fluid) for corticosterone and aldosterone, the main corticosteroids in mice. Based on the effects of corticosterone on thymus weight, replacement with 3 micrograms/ml corticosterone given in the drinking fluid (0.9% NaCl) for one week was found to be appropriate. The appropriate replacement dose for aldosterone was found by giving aldosterone to adrenalectomized (ADX) mice in the drinking fluid in combination with 3 micrograms/ml corticosterone. The combination of 3 micrograms/ml corticosterone + 30 ng/ml aldosterone resulted in a plasma ratio of corticosterone/aldosterone which most closely approximated the ratio seen in sham-ADX control animals. The physiologic adequacy of the corticosteroid replacement doses resulting from this study were clearly demonstrated in subsequent behavioral experiments where blockade of the memory-enhancing effects of piracetam by adrenalectomy were overcome by replacement with either 3 micrograms/ml corticosterone or 30 ng/ml aldosterone given in the drinking fluid.
Collapse
Affiliation(s)
- A Häusler
- Research Department, Pharmaceuticals Division, CIBA-GEIGY Ltd., Basel, Switzerland
| | | | | | | | | |
Collapse
|
16
|
Magnani M, Pozzi O, Biagetti R, Banfi S, Dorigotti L. Oxiracetam antagonizes the disruptive effects of scopolamine on memory in the radial maze. Psychopharmacology (Berl) 1992; 106:175-8. [PMID: 1549645 DOI: 10.1007/bf02801969] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The effects exerted by oxiracetam on the disruption of performance induced by scopolamine in the radial arm maze were investigated in overtrained rats. Scopolamine induced a dose-related decrease in the efficiency of responding and an increase of running time. The effect of the SC injection of 0.2 mg/kg scopolamine on the efficiency of responding was antagonized by the IP administration of 30 mg/kg oxiracetam, while the effect on running time induced by the same dose of scopolamine was not. Physostigmine (0.3 mg/kg SC) antagonized both effects of 0.2 mg/kg scopolamine. Methylscopolamine, at the dose of 0.2 mg/kg SC, was devoid of any effect on both parameters. Increasing the dose of methylscopolamine to 0.63 mg/kg did cause serious peripheral effects which eventually prevented some animals from completing the task. Similar peripheral effects were observed after administration of 0.63 mg/kg scopolamine. The effects of this dose of scopolamine on efficiency and running time were not antagonized by pretreatment with 100 mg/kg oxiracetam. Oxiracetam alone (30 or 100 mg/kg IP) did not modify the performance of previously trained rats. The present results suggest that oxiracetam selectively restores cholinergic mechanisms which are involved in learning and memory.
Collapse
Affiliation(s)
- M Magnani
- ISF Laboratories for Biomedical Research, Milano, Italy
| | | | | | | | | |
Collapse
|
17
|
Mondadori C, Ducret T, Häusler A. Elevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimetics. Psychopharmacology (Berl) 1992; 108:11-5. [PMID: 1410129 DOI: 10.1007/bf02245278] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Oral pretreatment of mice with aldosterone or corticosterone blocked the memory-enhancing effects of piracetam, pramiracetam, aniracetam and oxiracetam in a dose-related manner, without, however, impairing the animals' learning performance. The improvement of memory induced by physostigmine, arecoline, and tacrine (THA) was similarly inhibited. The fact that elevated steroid levels suppress the memory-enhancing effects of entirely different substances could indicate that these substances have a common site of action. In the light of new observations showing increased cortisol concentrations in Alzheimer patients, this steroid dependency of the effects of memory enhancers might explain why only a limited number of these patients respond to therapy with nootropics or cholinomimetics.
Collapse
Affiliation(s)
- C Mondadori
- Ciba-Geigy Ltd., Pharmaceutical Research Department, Basle, Switzerland
| | | | | |
Collapse
|
18
|
Mondadori C, Gentsch C, Hengerer B, Ducret T, Borkowski J, Racine A, Lederer R, Haeusler A. Pretreatment with aldosterone or corticosterone blocks the memory-enhancing effects of nimodipine, captopril, CGP 37,849, and strychnine in mice. Psychopharmacology (Berl) 1992; 109:383-9. [PMID: 1365851 DOI: 10.1007/bf02247712] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Oral pretreatment with aldosterone or corticosterone blocked the memory-enhancing effects of the calcium antagonist nimodipine, the ACE inhibitor captopril, the NMDA blocker CGP 37,849, and the glycine antagonist strychnine in a passive-avoidance test in mice. The memory-disturbing effects of phenobarbitone, diazepam, CGP 37,849 and scopolamine were not influenced by the hormonal pretreatment. These findings could indicate the involvement of a steroid-sensitive mechanism in drug-induced improvement of memory. In the light of clinical observations showing elevated cortisol levels in Alzheimer patients, the results might also explain why only a limited number of these patients respond to therapy with memory enhancers.
Collapse
Affiliation(s)
- C Mondadori
- Pharmaceuticals Division, CIBA-GEIGY Ltd, Basel, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Sutanto W, de Kloet ER. Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects. Med Res Rev 1991; 11:617-39. [PMID: 1662327 DOI: 10.1002/med.2610110604] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- W Sutanto
- Center for Bio-Pharmaceutical Sciences, Sylvius Laboratoria, University of Leiden, The Netherlands
| | | |
Collapse
|
20
|
Mondadori C, Ducret T, Borkowski J. How long does 'memory consolidation' take? New compounds can improve retention performance, even if administered up to 24 hours after the learning experience. Brain Res 1991; 555:107-11. [PMID: 1933323 DOI: 10.1016/0006-8993(91)90866-t] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The 'nootropics' are a new class of psychoactive substances that improve learning and memory. Their almost exclusive effect on memory may indicate that they act on processes specifically involved in information storage. When administered after the learning trial, these substances improve subsequent retention performance in mice, even if an interval of 8 h has elapsed between learning and treatment. CGS 5649B, a highly active new substance, is effective even after an interval of 24 h. Although consonant with the 'consolidation' hypothesis, the results may challenge prevailing notions about the formation of memory traces.
Collapse
Affiliation(s)
- C Mondadori
- CIBA-GEIGY Limited, Research Department, Basel, Switzerland
| | | | | |
Collapse
|